5-hydroxytryptophan gastroretentive dosage forms
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 12, 2023
Grant Date -
Feb 16, 2023
app pub date -
Jul 29, 2022
filing date -
Jul 30, 2021
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully